Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
DEAD-box helicase 31 (DDX31) is an ATP-dependent RNA and DNA helicase enzyme characterized by the conserved DEAD (Asp-Glu-Ala-Asp) motif. It belongs to the DEAD-box family, which is the largest group of RNA helicases and is structurally defined by two RecA-like domains connected by a flexible linker and conserved sequence motifs for RNA binding, ATP binding, and ATP hydrolysis[1][3][4][6]. DEAD-box helicases, including DDX31, act through unwinding short RNA duplexes and modulating secondary structure in a non-processive, non-sequence-specific manner, frequently acting as part of ribonucleoprotein complexes[4][6]. DDX31 plays a role in ribosome biogenesis and has been reported to regulate the p53-HDM2 pathway and rRNA transcription via interaction with nucleophosmin 1 (NPM1), particularly in the context of renal cell carcinoma[1][7]. While its full, unique functions remain undetermined, family members influence translation initiation, RNA splicing, cell growth, embryogenesis, and spermatogenesis. No approved drugs specifically target DDX31, nor is it established as a clinical biomarker or drug safety concern. However, its potential as a cancer-related therapeutic target and regulator of critical cellular processes makes it of growing investigational interest[1][3][7].
null (no drugs are reported to specifically target DDX31, but general mechanisms for DEAD-box helicases include inhibition of ATPase or helicase activity, affecting ribosome biogenesis and RNA processing)[1][4][6][7]
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on DEAD-box helicase 31 (DDX31).